✦ LIBER ✦

VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC)

✍ Scribed by P. A. Madrigal; G. P. Manga; I. Palomero; R. Garcia Gomez

Publisher: Springer
Year: 1982
Tongue: English
Weight: 175 KB
Volume: 7
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00254549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Doxorubicin, cyclophosphamide and VP16-2

Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer

✍ Joseph Aisner; Margaret Whitacre; David A. VanEcho; Margaret Wesley; Peter H. Wi 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 742 KB

Small cell lung cancer requires aggressive combination chemotherapy. The three active agents, doxorubicin (A) 45 mg/m2 i.v. day 1, cyclophosphamide (C) 1.0 mg/m2 i.v. day 1 and VP16-213 (E) 50 mg/m2/day i.v. days 1-5 were given together. The combination (ACE) was given every 21 days without chest ir

Treatment of small cell lung cancer with

Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy

✍ H. Cortés Funes; P. Dominguez; A. Perez Torrubia; E. Lanzos; M. Mendez; C. Mendi 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 505 KB

Fifty five patients with small cell lung cancer with treated with VP16-213 combination chemotherapy regimen in two consecutive series. The first series included 24 patients; 10 with limited and 14 with extensive disease were treated with VP16-213, 120 mg/m2 p.o. daily for 5 consecutive days, Cycloph

Chemotherapy combination with cyclophosp

Chemotherapy combination with cyclophosphamide (CTX) adriamycin (ADM), vincristine (VCR), and VP16-213 in small cell carcinoma of the lung (SCCL)

✍ J. M. Gracia; A. Jimenez 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 178 KB

Twenty-four evaluable patients with small cell carcinoma of the lung were treated with an escalating chemotherapy regimen including Cyclophosphamide, Adriamycin, Vincristine and VP16-213. The initial doses were CTX 800 mg/m2 i.v. day 1; ADR 50 mg/m2 i.v. day 1; VCR 1.4 mg/m2 day 1 weekly; and VP16-2

Vincristine, adriamycin, cyclophosphamid

Vincristine, adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung

✍ F. E. Eyben; Å. Arwidi; C. Hellekant; K. Jonsson; S. Å. Lindahl; W. Mattsson; L. 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 299 KB

Twelve patients with small-cell anaplastic carcinoma of the lung were treated with vincristine 1 mg/m2 i.v. day 1, adriamycin 50 mg/M2 i.v. day 1, cyclophosphamide 1,000 mg/m2 i.v. day 1, and etoposide 80 mg/m2 i.v. day 2, 4, 6 given on an outpatient basis and repeated at 3-week intervals. As consol

Enhanced radiation reaction following co

Enhanced radiation reaction following combination chemotherapy for small cell carcinoma of the lung, possibly secondary to VP16-213

✍ Richard J. Giever; Robert S. Heusinkveld; Michael R. Manning; G.Timothy Bowden 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 315 KB

Epipodophyllotoxin (VP16-213) in small c

Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy

✍ P. G. Harper; M. B. Dally; D. M. Geddes; S. G. Spiro; J. F. Smyth; R. L. Souhami 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 168 KB

Thirty-eight patients with small cell carcinoma of the bronchus resistant to initial chemotherapy with cyclophosphamide methotrexate and CCNU, were treated with VP16-213 alone in a dose of 120 mg/m2 i.v. on days 1, 3, and 5 every 3 weeks. Twelve patients died before three courses of treatment. In 26